Teva Pharmaceuticals will announce Q4 2024 results and 2025 guidance on January 29, 2025, via conference call.
Quiver AI Summary
Teva Pharmaceutical Industries Ltd. announced that it will release its fourth quarter and full year 2024 financial results, along with its financial guidance for 2025, on January 29, 2025, at 7:00 a.m. ET. Following the announcement, Teva will host a conference call and live webcast at 8:00 a.m. ET for which participants must register in advance. A replay of the webcast will be available on Teva's website within 24 hours. The press release also highlights Teva's long-standing commitment to improving health through pharmaceutical innovation and mentions potential risks related to forward-looking statements, urging caution against undue reliance on such projections.
Potential Positives
- Teva will provide its fourth quarter and full year 2024 financial results, indicating a commitment to transparency with stakeholders.
- The announcement of financial guidance for 2025 shows Teva's proactive approach in financial planning and strategy, which could inspire investor confidence.
- The scheduled conference call and webcast facilitate direct communication between the company and its investors, enhancing engagement and accessibility.
- Teva's ongoing commitment to innovation and health improvement, as detailed in the release, reinforces its position as a leader in the pharmaceutical industry.
Potential Negatives
- Teva's substantial indebtedness may pose significant risks to its financial stability, potentially impacting investor confidence.
- The company's ongoing reliance on its "Pivot to Growth" strategy indicates that it may still be struggling to establish a secure path for future growth, raising concerns among stakeholders.
- The cautionary note highlights numerous risks and uncertainties that could adversely affect the company's future performance, which may deter potential investors.
FAQ
When will Teva announce its financial results for 2024?
Teva will announce its fourth quarter and full year 2024 financial results on January 29, 2025, at 7:00 a.m. ET.
How can I participate in the conference call?
To participate, register in advance to obtain a local or toll-free phone number and personal pin for the call.
Will there be a live webcast of the conference call?
Yes, a live webcast of the conference call will be available on Teva's website on January 29, 2025, at 8:00 a.m. ET.
How soon will the webcast replay be available?
A replay of the webcast will be available within 24 hours after the conclusion of the call on Teva's website.
What is Teva's focus as a pharmaceutical leader?
Teva aims to enhance health through generics expertise and innovation in the discovery and development of modern medicine.
Disclaimer: This is an AI-generated summary of a press release distributed by GlobeNewswire. The model used to summarize this release may make mistakes. See the full release here.
$TEVA Insider Trading Activity
$TEVA insiders have traded $TEVA stock on the open market 5 times in the past 6 months. Of those trades, 0 have been purchases and 5 have been sales.
Here's a breakdown of recent trading of $TEVA stock by insiders over the last 6 months:
- CHRISTINE FOX (EVP, Head of U.S. Commercial) sold 19,388 shares.
- RICHARD DANIELL (Exec. VP, European Commercial) sold 98,943 shares.
- ANGUS GRANT (EVP, Business Development) sold 4,065 shares.
- ERIC A HUGHES (See "Remarks") has traded it 2 times. They made 0 purchases and 2 sales, selling 69,597 shares.
To track insider transactions, check out Quiver Quantitative's insider trading dashboard.
$TEVA Hedge Fund Activity
We have seen 261 institutional investors add shares of $TEVA stock to their portfolio, and 254 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- FMR LLC added 20,762,226 shares (+49.5%) to their portfolio in Q3 2024
- PHOENIX HOLDINGS LTD. removed 9,159,191 shares (-26.5%) from their portfolio in Q2 2024
- ARROWSTREET CAPITAL, LIMITED PARTNERSHIP added 9,095,106 shares (+156.7%) to their portfolio in Q3 2024
- VIKING GLOBAL INVESTORS LP added 7,567,533 shares (+inf%) to their portfolio in Q3 2024
- SLATE PATH CAPITAL LP removed 6,522,951 shares (-32.3%) from their portfolio in Q3 2024
- JANUS HENDERSON GROUP PLC added 4,732,374 shares (+7945.2%) to their portfolio in Q3 2024
- WILLIAM BLAIR INVESTMENT MANAGEMENT, LLC added 4,346,998 shares (+inf%) to their portfolio in Q3 2024
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard.
Full Release
TEL AVIV, Israel, Dec. 20, 2024 (GLOBE NEWSWIRE) --
Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) announced today that it will issue a press release on its fourth quarter and full year 2024 financial results, as well as on its financial guidance for 2025, on Wednesday, January 29, 2025, at 7:00 a.m. ET. Following the release, Teva will conduct a conference call and live webcast on the same day, at 8:00 a.m. ET.
In order to participate, please register in advance
here
to obtain a local or toll-free phone number and your personal pin.
A live webcast of the call will be available on Teva's website at:
.
Following the conclusion of the call, a replay of the webcast will be available within 24 hours on Teva's website.
About Teva
Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) is a global pharmaceutical leader, harnessing our generics expertise and stepping up innovation to continue the momentum behind the discovery, delivery, and expanded development of modern medicine. For over 120 years, Teva's commitment to bettering health has never wavered. Today, the company's global network of capabilities enables its ~37,000 employees across 58 markets to push the boundaries of scientific innovation and deliver quality medicines to help improve health outcomes of millions of patients every day. To learn more about how Teva is all in for better health, visit
.
Cautionary Note Regarding Forward-Looking Statements
This press release and the conference call may contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, which are based on management's current beliefs and expectations and are subject to substantial risks and uncertainties, both known and unknown, that could cause our future results, performance or achievements to differ significantly from that expressed or implied by such forward-looking statements. Important factors that could cause or contribute to such differences include risks relating to: our ability to successfully compete in the marketplace including our ability to successfully execute our Pivot to Growth strategy; our substantial indebtedness; our business and operations in general; compliance, regulatory and litigation matters; other financial and economic risks; and other factors discussed in this press release, in our Quarterly Report on Form 10-Q for the third quarter of 2024, and in our Annual Report on Form 10-K for the year ended December 31, 2023, including in the sections captioned "Risk Factors." Forward-looking statements speak only as of the date on which they are made, and we assume no obligation to update or revise any forward-looking statements or other information contained herein, whether as a result of new information, future events or otherwise. You are cautioned not to put undue reliance on these forward-looking statements.
Teva Media Inquiries
TevaCommunicationsNorthAmerica@tevapharm.com
Teva Investor Relations Inquires
TevaIR@Tevapharm.com
